ST易联众(300096) - 2019 Q1 - 季度财报

Financial Performance - Total revenue for Q1 2019 was CNY 105,820,606.40, representing an increase of 18.89% compared to CNY 89,009,549.04 in the same period last year[7]. - Net profit attributable to shareholders was CNY -20,827,377.48, a decrease of 3.28% from CNY -20,165,435.64 year-on-year[7]. - Basic and diluted earnings per share were both CNY -0.0484, a decrease of 3.20% from CNY -0.0469 in the same period last year[7]. - The company's operating profit was -27.78 million, a decrease of 15.92% year-on-year[19]. - Net profit for the current period was a loss of ¥26,208,038.73, compared to a loss of ¥20,906,837.22 in the previous period, worsening by about 25.4%[49]. - Operating profit for the current period was a loss of ¥27,784,518.76, compared to a loss of ¥23,968,296.76 in the previous period, reflecting a decline of approximately 15.1%[49]. - Total comprehensive loss for the current period was ¥26,208,038.73, compared to a loss of ¥20,906,837.22 in the previous period, indicating an increase in losses of about 25.4%[50]. Cash Flow - Net cash flow from operating activities was CNY -122,909,482.46, reflecting a decline of 25.54% compared to CNY -97,904,388.14 in the previous year[7]. - Total cash inflow from operating activities was 133,405,531.01 CNY, while cash outflow was 256,315,013.47 CNY, resulting in a net cash flow deficit[57]. - Cash flow from investing activities showed a net outflow of -5,036,043.18 CNY, compared to -1,393,395.94 CNY in the previous period, reflecting increased investment expenditures[58]. - Cash inflow from financing activities was 91,000,000.00 CNY, with a net cash flow of 45,204,889.53 CNY, a significant increase from 4,945,818.71 CNY in the previous period[58]. - The ending balance of cash and cash equivalents decreased to 243,040,610.00 CNY from 311,289,735.85 CNY, indicating a reduction in liquidity[58]. - The company received 90,150,000.00 CNY from borrowings, up from 80,000,000.00 CNY in the previous period, showing reliance on debt financing[62]. - Total cash inflow from operating activities was 105,759,629.46 CNY, down from 182,858,402.94 CNY, indicating a decline in revenue generation[61]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,915,622,997.37, a slight increase of 0.03% from CNY 1,914,957,108.71 at the end of the previous year[7]. - Current liabilities totaled CNY 808,432,841.84, up from CNY 781,284,873.36, reflecting an increase of approximately 3.9%[40]. - The company's total liabilities reached CNY 1,107,530,164.59, an increase from CNY 1,081,506,237.20, marking a growth of about 2.3%[40]. - Total liabilities reached CNY 1,081,506,237.20, with current liabilities at CNY 781,284,873.36[65]. - The company’s retained earnings were reported at CNY 250,158,960.13[65]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 30,281[10]. - The top shareholder, Zhang Xi, holds 16.21% of the shares, amounting to 69,681,649 shares, with 52,261,237 shares pledged[10]. - Micro Medical Group increased its shareholding to 41,200,000 shares, representing 9.58% of the total share capital as of March 31, 2019, up from 21,000,000 shares or 4.88% prior to the increase[29]. - The company’s major shareholder, Zhang Xi, retained 128,875,867 shares, accounting for 29.97% of the total share capital after the transfer of 36,775,000 shares[26]. - The company did not engage in any repurchase transactions among the top 10 shareholders during the reporting period[11]. Operational Highlights - The company plans to enhance its core competitiveness through continuous R&D of new technologies and products[22]. - The company is actively expanding its business in the healthcare sector, public services, and big data fields to increase market share[19]. - The company has implemented measures to mitigate technology risks, including patent applications and internal confidentiality systems[22]. - Research and development expenses rose to ¥29,615,998.59, up from ¥23,188,014.68, indicating a growth of approximately 27.7%[47]. Other Financial Metrics - Other receivables increased by 49.15% compared to the beginning of the year, mainly due to new factoring business interest[17]. - Inventory increased by 48.24% compared to the beginning of the year, primarily due to the increase in project equipment[17]. - Investment income increased by 61.79% year-on-year, mainly due to profits from certain affiliated companies[18]. - Other income increased to ¥4,733,035.81 from ¥1,856,697.74, marking a growth of about 154%[47]. - The company incurred financial expenses of ¥3,551,134.28, down from ¥4,500,865.83, a decrease of approximately 21%[47].